The AI That Reads ECGs Better Than Your Cardiologist with Martin Herman
The Crux of Medtech · The Crux of Medtech
Audio is streamed directly from the publisher (anchor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode of the Crux of Cardio, host Jordan Burgin is joined by Martin Herman, co-founder and CEO of Powerful Medical the AI-powered cardiac diagnostics company behind PM Cardio.
Martin shares how a software engineering background, a medical student brother, and a search for a truly pioneering problem led him to build an AI platform that can now diagnose 46 cardiovascular conditions from a single 12-lead ECG with over 120,000 doctors already using it in clinical practice.
They cover the journey from early scepticism to clinical proof, the brutal reality of MedTech fundraising, and what FDA breakthrough designation means for Powerful Medical's imminent US commercial launch.
Key Topics:
How Powerful Medical identified the ECG as cardiology's biggest unsolved problem
Building AI that outperforms experienced cardiologists on the hardest cases
The clinical and commercial case for PM Cardio in US heart attack centres
FDA breakthrough designation and the road to US approval this summer
Raising €46M in non-dilutive EU grant funding and what comes next
Winning MedTech Innovator and what it means for partnerships and validation
Related Insights:
Why starting with the biggest clinical sceptics is actually a growth strategy
How 64 American physician-investors validated the product with $3.5M in funding
The difference between pre- and post-ChatGPT AI fundraising environments
Why young founders have a structural advantage in MedTech and how to use it
Core Challenges:
Beyond the cardiologist, almost no clinician can reliably read an ECG creating a critical diagnostic gap at the first point of patient contact that PM Cardio is designed to close.
US hospitals chasing heart attack accreditation KPIs are generating false positive rates as high as 70–80%, costing up to $15,000 per unnecessary cath lab activation. PM Cardio reduces false positives by ~90% while maintaining diagnostic sensitivity.
Regulatory fragmentation across 27 EU healthcare markets and the complexity of US FDA approval has been the single biggest bottleneck to commercial scale, despite overwhelming clinical evidence.
Tune in now to hear how Martin Herman turned a software engineering background and a medical student brother into a platform already saving thousands of lives and why the biggest breakthrough may still be ahead.